Sonus falls after Tocosol miss

SNUS dropped $3.65 (84%) to $0.70 on 37.3 million shares on Monday after IV Tocosol paclitaxel missed the primary endpoint of a non-inferior objective response rate vs. Taxol paclitaxel in the Phase I...